CalciMedica files for up to $25 million at-the-market stock offering

CalciMedica, Inc. filed a prospectus supplement dated September 30, 2026 for an at-the-market offering of up to $25,000,000 of common stock. The company had previously entered into an offering agreement with H.C. Wainwright & Co., LLC, under which it may sell shares having an aggregate gross sales price of up to $25,000,000 through Wainwright acting as sales agent.¹

CalciMedica's common stock trades on the Nasdaq Capital Market under the symbol "CALC," and closed at $1.695 per share on September 28, 2026.¹ Under the terms disclosed, Wainwright's commission is set at 3.0% of the gross sales price for each share sold.¹

The filing is part of a larger shelf registration. The company may sell up to $125,000,000 in total securities under the shelf, of which the $25,000,000 common stock offering is included.¹

CalciMedica said it intends to use the proceeds broadly. The company plans to apply net proceeds to general corporate purposes, which may include research and development expenses, clinical trial expenses, capital expenditures and working capital.¹

The filing also details the company's financial position as of mid-2026. As of June 30, 2026, CalciMedica's net tangible book value stood at about $5.5 million, equal to $0.90 per share after retroactively applying the 1-for-5 reverse stock split.¹ Assuming full sale of the offering at the September 28 closing price, the company's adjusted net tangible book value would rise to approximately $29.5 million, or $1.41 per share, representing an increase of $0.51 per share for existing stockholders and dilution of $0.285 per share for new investors in the offering.¹

On the clinical side, the filing notes that following FDA feedback in July 2026, CalciMedica is preparing for a potential Phase 2b trial of Auxora in acute pancreatitis, intended to inform a future Phase 3 program.¹